|
|
Evan D. Muse, Silvana Obici, Sanjay Bhanot, Brett P. Monia, Robert A. McKay, Michael W. Rajala, Philipp E. Scherer, Luciano Rossetti
J Clin Invest. 2004;
114(2):232
doi:10.1172/JCI21270
Abstract |
Full text
| PDF

R
esistin is an adipose-derived hormone postulated to link adiposity to insulin resistance. To determine whether resistin plays a causative role in the development of diet-induced insulin resistance, we lowered circulating resistin levels in mice by use of a specific antisense oligodeoxynucleotide (ASO) directed against resistin mRNA and assessed in vivo insulin action by the insulin-clamp technique. After 3 weeks on a high-fat (HF) diet, mice displayed severe insulin resistance associated with an approximately 80% increase in plasma resistin levels. In particular, the rate of endogenous glucose production (GP) increased more than twofold compared with that in mice fed a standard chow. Treatment with the resistin ASO for 1 week normalized the plasma resistin levels and completely reversed the hepatic insulin resistance. Importantly, in this group of mice, the acute infusion of purified recombinant mouse resistin, designed to acutely elevate the levels of circulating resistin up to those observed in the HF-fed mice, was sufficient to reconstitute hepatic insulin resistance. These results provide strong support for a physiological role of resistin in the development of hepatic insulin resistance in this model.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(22)
| Title and authors |
Publication |
Year |
AMPK inhibition in health and disease.
Benoit Viollet, Sandrine Horman, Jocelyne Leclerc, Louise Lantier, Marc Foretz, Marc Billaud, Shailendra Giri, Fabrizio Andreelli
|
Critical Reviews in Biochemistry and Molecular Biology
|
2010 |
Resistin: a newly identified chemokine for human CD4-positive lymphocytes
D. Walcher, K. Hess, R. Berger, M. Aleksic, P. Heinz, H. Bach, R. Durst, A. Hausauer, V. Hombach, N. Marx
|
Cardiovascular Research
|
2009 |
Retinol-Binding Protein-4 in Women With Untreated Essential Hypertension
Anna Solini, Eleonora Santini, Stephanie Madec, Chiara Rossi, Elza Muscelli
|
Am J Hypertens
|
2009 |
Emerging drugs for non-alcoholic fatty liver disease
Alessandro Federico, Marco Niosi, Camillo Del Vecchio Blanco, Carmela Loguercio
|
Expert Opin. Emerging Drugs
|
2008 |
AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function.
Ming-Hui Zou, Yong Wu
|
Clin. Exp. Pharmacol. Physiol.
|
2008 |
AMPK: a metabolic gauge regulating whole-body energy homeostasis
Ricardo Lage, Carlos Diéguez, Antonio Vidal-Puig, Miguel López
|
Trends in Molecular Medicine
|
2008 |
Resistin gene polymorphisms and progression of glycaemia in southern Chinese: a 5-year prospective study
Jian Yu Xu, Pak C. Sham, Aimin Xu, Annette W. K. Tso, Nelson M. S. Wat, King Yip Cheng, Carol H. Y. Fong, Edward D. Janus, Karen S. L. Lam
|
Clinical Endocrinology
|
2007 |
Prolonged exposure to resistin inhibits glucose uptake in rat skeletal muscles
Hong-qi FAN, Nan GU, Feng LIU, Li FEI, Xiao-qin PAN, Mei GUO, Rong-hua CHEN, Xi-rong GUO
|
Acta Pharmacologica Sinica
|
2007 |
Nonalcoholic fatty liver disease and cardiovascular disease risk
Roger K. Schindhelm, Michaela Diamant, Robert J. Heine
|
Curr Diab Rep
|
2007 |
Hypothalamic resistin induces hepatic insulin resistance
Evan D. Muse, Tony K.T. Lam, Philipp E. Scherer, Luciano Rossetti
|
J. Clin. Invest.
|
2007 |
|